[HTML][HTML] Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019

…, S Abd-Elsalam, G Abebe, A Abedi, AP Abhari… - The Lancet, 2022 - thelancet.com
Background Reducing the burden of death due to infection is an urgent global public health
priority. Previous studies have estimated the number of deaths associated with drug-…

[HTML][HTML] Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

…, M Abbasian, H Abbastabar, AP Abhari… - The Lancet Global …, 2023 - thelancet.com
Background Peripheral artery disease is a growing public health problem. We aimed to
estimate the global disease burden of peripheral artery disease, its risk factors, and …

COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?

…, M Ganjalikhani-Hakemi, M Rayani, AP Abhari… - Multiple Sclerosis and …, 2021 - Elsevier
Background COVID-19 is speculated to increase the likelihood of relapsing-remitting
multiple sclerosis (RRMS) exacerbation. Objective To investigate the association between …

Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis

…, M Salari, M Baratian, S Mahdavi, AP Abhari… - Journal of Neurology …, 2022 - jnnp.bmj.com
Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination …

Prediabetes and COVID-19 severity, an underestimated risk factor: A systematic review and meta-analysis

M Heidarpour, AP Abhari, N Sadeghpour… - Diabetes & Metabolic …, 2021 - Elsevier
Background and aims The novel coronavirus disease 2019 (COVID-19) has rapidly spread
through the whole globe. Since the beginning of the outbreak, some individuals were more …

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis

M Etemadifar, AP Abhari, H Nouri… - Human vaccines & …, 2022 - Taylor & Francis
To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among
people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were …

[HTML][HTML] Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study

M Etemadifar, AP Abhari, H Nouri, M Salari, S Maleki… - BMC neurology, 2022 - Springer
Background Some current evidence is pointing towards an association between COVID-19
and worsening of multiple sclerosis (MS), stressing the importance of preventing COVID-19 …

MRI signs of CNS demyelinating diseases

…, M Salari, M Rayani, A Aghababaee, AP Abhari - Multiple Sclerosis and …, 2021 - Elsevier
The differential diagnosis of the central nervous system (CNS) demyelinating diseases can
be greatly facilitated by visualization and appreciation of pathognomonic radiological signs, …

Serum vitamin D levels and COVID-19 during pregnancy: A systematic review and meta-analysis

…, M Yazdi, M Fakhrolmobasheri, AP Abhari - Clinical Nutrition …, 2022 - Elsevier
Background Serum vitamin D levels are reported to be associated with the risk of incidence
and severity of COVID-19 in the general population. During pregnancy, immune system …

Systematic Review and Meta-Analysis of Levothyroxine Effect on Blood Pressure in Patients with Subclinical Hypothyroidism

B Darouei, R Amani-Beni, AP Abhari… - Current Problems in …, 2023 - Elsevier
This study aims to evaluate the effect of levothyroxine therapy on blood pressure (BP) in
patients with subclinical hypothyroidism (SCH). Were searched Six databases, and randomized …